Dealroom-2021年欧洲卫生与生物技术风险投资报告（英文）-2021.6-30页_13mb

European Health & Biotech VC Funding Summary

Core Content

The document provides an overview of the European Healthtech and Biotech investment landscape, highlighting the growth and key trends in venture capital funding, market opportunities, and the role of various stakeholders such as governments, insurers, and corporations.

Main Points

• Investment Growth:
  Global investment in health and biotech is on a record pace and could reach $100B this year.
  European Healthtech and Biotech investments are also growing rapidly, with notable figures in funding and enterprise value.

• Market Value:
  European Healthtech companies are now worth $48 billion, while combined Healthtech and Biotech companies are valued at $232 billion.

• Unicorn Companies:
  There are 13 Healthtech unicorns and 40 future unicorns in Europe, with 57% located in the UK and France.
  For Biotech, there are 31 unicorns and 51 future unicorns, with 40% in the UK and France.

• Key Sectors:
  The biggest segments in European Healthtech are digital pharmacy and digital care.
  Other notable areas include continuous vital monitoring, dental monitoring, diabetes glucose level monitoring, and digestive tracking.

• Funding Totals:
  Continuous vital monitoring has combined funding of €283M.
  Dental monitoring has combined funding of €50M.
  Diabetes glucose level monitoring has combined funding of €357M.
  Digestive tracker has combined funding of €21M.

• Regulatory and Market Dynamics:
  European healthcare systems are characterized by government and insurer influence, with a slower adoption process compared to the US.
  In the US, employers have a significant role in private insurance and can adopt innovation more easily.

• Healthcare Systems Overview:
  Healthcare is one of the largest household spending categories, but most of it is indirect (insurance and tax).
  Governments and insurers in Europe aim to control costs and improve outcomes, which creates opportunities for tech companies.

• Country-Specific Insights:

  • Germany: Adopted the Digital Healthcare Act in 2019, and offers €500 incentives for startup video consultations.
  • UK: Has the NHSX Innovation Accelerator and has pledged $330M for AI in health.
  • Sweden: Has integrated electronic health records and e-prescriptions since 2018.
  • France: Leads in telemedicine with KRY (Livi) and Doctolib as market leaders.

• Investor Landscape:
  The document highlights the most active investors in European Healthtech and Biotech, and introduces the new platform healthDealroom.co for accessing over 41,000+ healthtech startups and related data.

Key Information

• Market Trends:
  B2C Healthtech is scaling faster than B2B, although B2B presents a significant opportunity.
  The convergence of Biopharma and Healthtech is creating new opportunities for innovation and collaboration.

• Regulatory Impact:
  Regulations in Europe are shaping consumer habits and expectations.
  For example, Greeks use more antibiotics, while Germans have more hospital beds and doctor consultations.

• Funding Opportunities:
  Startups in the Healthtech and Biotech sectors have access to substantial funding, with notable figures in combined investment amounts.

• Platform Introduction:
  healthDealroom.co is the new hub for Healthtech, providing a database of companies, investors, people, and innovations.

Conclusion

The European Healthtech and Biotech sectors are experiencing rapid growth, with increasing investment, a strong presence of unicorns, and a dynamic investor landscape. The regulatory environment and healthcare system structures play a crucial role in shaping the market, while the convergence of Biopharma and Healthtech opens new avenues for innovation and value creation.